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Sevelamer hydrochloride attenuates kidney and cardiovascular
calcifications in long-term experimental uremia.
Background. In chronic renal failure (CRF), hyperphospha-
temia and an elevated calcium-phosphate product are associ-
ated with vascular calcification and increased cardiovascular
morbidity and mortality. Previous data have demonstrated that
3-month treatment of uremic rats with sevelamer was associ-
ated with less nephrocalcinosis compared to calcium carbonate
(CaCO3), despite similar control of serum phosphorus, calcium-
phosphorus product (Ca x P product), and secondary hyper-
parathyroidism. There was no evidence of aortic calcification
after 3 months of uremia (J Am Soc Nephrol 13:2299–2308,
2002). The present studies explore the influence of sevelamer
and CaCO3 on cardiovascular and kidney calcifications in long-
term experimental uremia over 6 months.
Methods. Normal and 5/6 nephrectomized rats (U) were fed
a high phosphorus (HP) diet for 6 months. Two phosphate
binders, CaCO3 and sevelamer, were administered and their
influence on hyperphosphatemia, secondary hyperparathyroid-
ism, kidney/myocardial/aortic calcification, and renal function
was compared.
Results. All uremic rats began the study with the same de-
gree of renal failure. Sevelamer was as effective as CaCO3 in
reducing serum phosphorus, Ca x P product, and attenuating
secondary hyperparathyroidism. Despite similar serum choles-
terol levels, rats in the U-HP sevelamer group had markedly
lower calcium deposition in the myocardium and aorta (myo-
cardium, 72  4 g/g wet tissue; aorta, 736  156 g/g wet
tissue) compared to rats in either the U-HP  CaCO3 group
(myocardium, 179 48, P 0.05; aorta, 1308 343, P 0.05)
or the U-HP group (myocardium, 98  10, NS; aorta, 2150 
447, P 0.05). Dual immunohistochemical analysis for calcium
and endothelial cell markers demonstrated that myocardial
calcium deposition was intravascular within capillaries. Fur-
thermore, calcium deposition in the kidney of uremic rats
treated with sevelamer (582  111 g/g wet tissue) was lower
than that found in uremic rats treated with CaCO3 (1196 
180 g/g wet tissue). Sevelamer-treated rats had less deteriora-
tion in renal function with an associated lower serum creatinine,
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higher creatinine clearance, and less proteinuria. There was no
difference in overall mortality between the three experimental
groups.
Conclusion. In long-term experimental CRF, in addition to
controlling serum phosphorus and secondary hyperparathy-
roidism as efficiently as CaCO3, treatment with the phosphate-
binder sevelamer attenuates vascular and kidney calcification.
A higher incidence of coronary artery and cardiac
valve calcification occurs in dialysis patients compared
to the general population [1–4]. Ectopic or vascular calci-
fication in chronic renal failure (CRF) is associated with
elevated levels of serum phosphorus and calcium-phos-
phate (Ca  P) product and is likely an important con-
tributor to increased cardiovascular morbidity and mor-
tality [5–8].
Vascular calcification in renal failure patients was pre-
viously considered a passive process resulting from depo-
sition of calcium-phosphate crystals in the setting of an
elevated Ca x P product and secondary hyperparathy-
roidism. Recent studies, however, suggest that vascular
calcification is instead an active, cell-mediated process
in which vascular smooth muscle cells develop bone-
forming functions [9–12]. The mechanisms mediating
and the treatment of this ectopic calcification remain
incompletely defined [6]. In vitro studies by Jono et al
[13] have demonstrated that high inorganic phosphate
levels, greater than 1.4 mmol/L, increase human smooth
muscle cell calcification rates and increase the expression
of the osteoblastic differentiation markers, osteocalcin
and Osf2/Cbfa-1, via a sodium-phosphate cotransporter
called Pit-1. Additional in vitro studies by Chen et al
[14] have shown that phosphorus and other factors in
uremic serum increase osteopontin expression and calci-
fication in bovine vascular smooth muscle cells [14]. Fi-
nally, a recent clinical trial published by Chertow, Burke,
and Raggi [15] revealed that sevelamer, when compared
to calcium-based phosphate binders, attenuated the pro-
gression of coronary and aortic calcification in hemodial-
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ysis patients as identified by electron beam computed
tomography. Thus, the control of hyperphosphatemia
with phosphate binders in patients with CRF may not
only prevent a worsening Ca P product and secondary
hyperparathyroidism, but also influence the develop-
ment of the active, cell-mediated process of vascular
calcification.
In previous years, the most commonly used phosphate
binders contained either aluminum or calcium salts, such
as calcium carbonate (CaCO3) or acetate. Whereas alu-
minum exposure may cause neurologic, skeletal, and he-
matologic toxicity [16–17], calcium-based phosphate
binders can lead to hypercalcemia and potentially worsen
the risk of soft tissue and cardiovascular calcifications
[18–20]. To avoid these side effects, an aluminum- and
calcium-free phosphate binder, sevelamer hydrochlo-
ride, has been developed. Sevelamer is effective in con-
trolling hyperphosphatemia and reducing serum Ca  P
product levels in dialysis patients [21–23].
Our group recently published the results of a study
comparing the effects of the two phosphate binders
CaCO3 and sevelamer in a 3-month experimental model
of uremia. Despite an equal control of hyperphosphate-
mia and secondary hyperparathyroidism, uremic rats on
a high phosphate diet and treated with sevelamer were
noted to have less nephrocalcinosis compared to uremic
rats treated with CaCO3. Uremic control rats fed a high
phosphate diet without a phosphate binder had the great-
est degree of kidney calcification. Furthermore, uremic
rats treated with either of these phosphate binders were
found to have decreased calcification in the myocardium
and liver compared to uremic control rats. Uremic rats on
sevelamer also had better renal function after 3 months
compared to uremic controls and those rats on CaCO3.
There was no evidence of aortic vascular calcification
after 3 months of uremia in either uremic controls or
those rats treated with phosphate binders [24].
Based on these findings, the present studies were con-
ducted in uremic rats fed a high phosphate diet to address
any differences between 6-month treatment with seve-
lamer and CaCO3 on vascular calcification, kidney calci-
fication, and renal function. Our findings indicate that
sevelamer attenuated kidney and cardiovascular calcifi-
cation more adequately than CaCO3, despite a similar
control of serum phosphorus, Ca  P product, parathy-




Renal insufficiency was induced by 5/6 nephrectomy
in 5 to 6 weeks-old female Sprague-Dawley rats, weighing
200 to 225 g. In this procedure, several branches of the
left renal artery were ligated and the right kidney excised.
After 7 days of uremia, blood was taken to determine
serum creatinine, calcium, and phosphorus. Rats were
subsequently divided into three experimental groups,
each with similar serum creatinine and serum Ca  P
product values. The three groups of uremic rats were fed
a high phosphorus diet (0.9% phosphorus; 0.6% calcium,
and 20% protein) for 6 months. Group 1 (38 rats), uremic
5/6 nephrectomized rats (U) fed a high phosphorus diet
(HP) (U-HP), received no phosphate binder and served
as the uremic control for the deleterious effects of pro-
longed high phosphorus intake. Two phosphate binders
were compared. Group 2 (30 rats), U-HP  CaCO3
(U-HP  C), received 3% CaCO3 as the phosphate
binder, whereas group 3 (29 rats), U-HP  sevelamer
(U-HP  S), received 3% sevelamer. An additional
group of rats with normal kidney function was fed a
similar high phosphorus diet and served as a nonuremic
control group. Powdered diets were purchased from Dy-
ets, Inc. (Bethlehem, PA, USA). CaCO3 (Sigma Chemi-
cal Co., St. Louis, MO, USA) and sevelamer hydrochlo-
ride (RenaGel) (GelTex Pharmaceuticals, Inc., Waltham,
MA, USA) were added to the powdered, high phospho-
rus diet. The dose (3%) of sevelamer and CaCO3 was de-
fined in pilot studies which demonstrated that 3% seve-
lamer and CaCO3 were equally effective in reducing serum
phosphorus in uremic rats fed the same high phosphorus
diet utilized in the present studies. On average, rats con-
sumed approximately 20 g of powdered diet per day.
Following 5/6 nephrectomy, rats were weighed monthly
and then placed into metabolic cages during the last 5
days of the 6-month treatment. Twenty-four–hour urine
samples were collected and daily dietary intake monitored.
Average 24-hour urinary excretion of calcium, phospho-
rus, and protein was measured during the last 3 days of
treatment. After 6 months, rats were killed and blood
was drawn from the dorsal aorta for analytic determina-
tions. Parathyroid glands were microsurgically removed
and weighed using a microbalance (CAHN-31) (Orion
Instruments, Inc., Boston, MA, USA).
The remnant kidney and the entire myocardium were
removed from rats at the time of the sacrifice, weighed
on a microbalance, and cut into three pieces perpendicu-
lar to the longitudinal axis. One piece from each tissue
was rinsed in phosphate buffered saline (PBS) and em-
bedded in paraffin. The two remaining pieces were care-
fully snap-frozen for calcium deposition analysis.
Aortas were dissected and three (0.5 cm) pieces from
the descending thoracic aorta to the iliac branch were
removed per rat (at approximately the same anatomic
level). Each sample was then cut into two pieces. One
piece was weighed on a microbalance and retained for
measurements of calcium deposition; the other was
rinsed in PBS and embedded in paraffin.
All experimental protocols were approved by the Ani-
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mal Studies Committee at Washington University School
of Medicine.
Analytic determinations
Urine samples were acidified and analyzed for 24-
hour excretion of creatinine, total protein, calcium, and
phosphorus. Serum and urinary levels of phosphate and
creatinine, as well as urinary protein, were determined
using an autoanalyzer (COBAS-MIRA Plus, Branch-
burg, NJ, USA). Total serum and urinary calcium were
measured by atomic absorption spectrophotometry using
a Perkin-Elmer 1100B spectrophotometer (Perkin-Elmer,
Norwalk, CT, USA). Creatinine clearances were calcu-
lated using the standard formula:
CCr  UCr (mg/dL)  Vu (mL in 24 hours)/[1440 min
 SCr (mg/dL)]
where CCr is creatinine clearance, UCr is urinary clear-
ance, Vu is urinary volume, and SCr is serum creatinine.
Urinary calcium, phosphorus, and protein were ex-
pressed as milligrams excreted in 24 hours. Intact PTH
levels were measured by an immunoradiometric assay
specific for intact rat PTH (Immutopics, San Clemente,
CA, USA).
Quantification of calcium deposition in kidney,
myocardium, and aorta
Calcium content in remnant kidney, myocardium, and
aorta was measured as previously described by Jono et al
[13]. Tissue (three samples from each remnant kidney,
myocardium, and aorta) was weighed and decalcified
with 0.6 N HCl for 24 hours. Calcium content in HCl
supernatants was determined by atomic absorption spec-
trophotometry. Results were corrected by wet tissue
weight and expressed as micrograms calcium/gram wet
tissue.
Kidney, myocardial, and aortic morphology
Five-micrometer tissue sections were stained with he-
matoxylin-eosin and processed for light microscopy. Sec-
tions were examined for calcium deposition using von
Kossa staining. Briefly, slides were deparaffinized, hy-
drated with water, incubated in 5% silver nitrate solution
(Sigma S-01334) (Sigma Chemical Co.) for 1 hour, rinsed
four times with distilled water, followed by a thiosulphate
solution for 5 minutes, and counterstained with nuclear
fast red solution for 5 minutes. Slides were then rinsed
in tap water, dehydrated, cleared in 95% ethyl alcohol,
100% ethyl alcohol, and xylene, and cover slips were
mounted. Semiquantitative assessment of calcification
was performed as follows. The entire kidney, myocar-
dium, and aortic sections were examined and all foci of
calcification were counted (four sections per animal and
a total of six rats per group). Precise localization of
calcium deposits within the myocardium was aided by
immunohistochemical staining of endothelial cells with
antibody to factor VIII. Briefly, slides were deparaffin-
ized, hydrated, immersed in citrate buffer (pH 6.0) for
10 minutes (2), and stained with polyclonal antibody to
human factor VIII (1:1000) overnight (Sigma Chemical
Co.). Slides were then rinsed, incubated with universal
Link antibody (Biocare, CA, USA), and developed with
diabenzidine (DAB). Endothelial cells lining arterioles
and capillaries were highlighted with this stain. Histo-
logic features were quantified by three different individu-
als blinded to treatment.
Statistical analyses
Analysis of variance (ANOVA) was employed to as-
sess statistical differences between all experimental
groups, except for mortality rates, in which a chi-square
test was performed. Multiple comparisons using the
stringent Bonferroni test measured the statistical signifi-
cance of the differences between every possible two-
group comparison. An unpaired, two-tailed t test was
used to compare time points at baseline and 6 months
within experimental groups.
RESULTS
Serum biochemistries (i.e., calcium, phosphorus, CaP
product, creatinine, and cholesterol), renal function, mark-
ers of secondary hyperparathyroidism, and calcium de-
position in the kidney, myocardium, and aorta were com-
pared between the three groups of rats (U-HP, U-HPC,
and U-HP  S).
Effects of sevelamer and CaCO3 on
serum biochemistries
After 6 months of uremia, serum creatinine increased
from baseline in U-HP and U-HP  C rats, but not in
U-HP  S rats (Table 1). Serum phosphorus and Ca  P
product were significantly lower in both U-HP  S and
U-HPC rats compared to U-HP control rats. Although
there was a trend toward lower levels in U-HP  S rats,
no statistical difference was found in serum phosphorus
and Ca  P product between U-HP  S and U-HP 
C rats (P  0.29 comparing phosphorus levels). Serum
calcium levels were also similar among the three uremic
groups after 6 months of uremia. Acid-base balance (se-
rum bicarbonate and pH) and cholesterol levels were
not statistically different among the three uremic groups.
Effects of sevelamer and CaCO3 on body weight
Baseline mean body weights for U-HP, U-HP  S,
and U-HP  C groups, respectively, were 217  21 g,
215  18 g, and 209  9 g. Those rats surviving to 6
months of uremia in U-HP, U-HP  S, and U-HP  C
groups had the following mean body weights: 298 10 g,
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Table 1. Serum chemistries
N-HP (N  6) U-HP (N  6) U-HP  S (N  6) U-HP  C (N  6)
Creatinine mg/dL
Baseline 0.700.05 1.50.1 1.50.1 1.50.1
6 months 0.880.03 2.30.3 1.50.1b 2.00.3
Phosphorus mg/dL
Baseline 4.50.4 9.60.4 9.40.5 9.60.3
6 months 4.50.5 10.91.3 5.90.6a,c 6.71.1a,c
Calcium mg/dL
Baseline 9.40.3 9.30.2 9.40.3 9.30.3
6 months 9.20.2 9.30.2 9.20.3 9.30.3
Ca  P product mg2/dL2
Baseline 424 877 878 890.8
6 months 424 10114 545a,c 618b,c
pH
6 months 7.350.01 7.250.01 7.310.02 7.260.04
HCO3 mEq/L
6 months 24.80.9 20.51.1 21.50.7 21.51.2
Cholesterol mg/dL
6 months 986 20411 20326 16324
Uremic (5/6 nephrectomized) rats underwent one of the following experimental protocols for 6 months: uremic control  high phosphorus diet (U-HP), uremic 
HP diet  3% sevelamer (U-HP  S), uremic  HP diet  3% calcium carbonate (U-HP  C). Values represent the MeanSEM; N  number of rats.
aP  0.01 vs. U-HP from analysis of variance (ANOVA) and Bonferroni analysis
bP  0.05 vs. U-HP from ANOVA and Bonferroni analysis
cP  0.01 comparing baseline and uremia 6 month time-points, using two-tailed t test
Table 2. Creatinine clearance, urinary protein, phosphorus, and calcium
U-HP (N  6) U-HP  S (N  6) U-HP  C (N  6)
Creatinine clearance mL/min 0.460.08 0.740.09b,c 0.480.08
Urinary protein mg/24 hours 25947 16012a,b 26828
Urinary calcium mg/24 hours 1.830.1 3.170.6 3.770.6b
Urinary phosphorus mg/24 hours 30.82.5 37.91.7c 26.63.2
Uremic (5/6 nephrectomized) rats underwent one of the following experimental protocols for 6 months: uremic control  high phosphorus diet (U-HP), uremic 
HP diet  3% sevelamer (U-HP  S), Uremic  HP diet  3% calcium carbonate (U-HP  C). Values represent the MeanSEM; N  number of rats.
aP  0.01 vs. U-HP  C; bP  0.05 vs. U-HP; cP  0.05 vs. U-HP  C, from analysis of variance (ANOVA) and Bonferroni analysis
332  11 g, and 294  9 g, respectively. U-HP  S rats
had significantly higher body weights compared to U-HP
and U-HP  C rats after 6 months of uremia.
Effects of sevalemer and CaCO3 on mortality
Mortality rates at six months were high among all ure-
mic groups: U-HP 84%, U-HP S 79%, and U-HP  C
80%. These values did not differ significantly between
groups (P  0.64).
Effects of sevelamer and CaCO3 on creatinine
clearance, urinary protein, calcium, and
phosphorus excretion
As shown in Table 2, creatinine clearance was equally
impaired in CaCO3-treated rats and uremic controls. Sev-
elamer-treated rats had higher creatinine clearances and
lower urinary protein excretion compared to the other
two groups of uremic rats. Treatment with CaCO3 was
associated with higher urinary calcium excretion com-
pared to uremic controls, but did not differ with that of
sevelamer treatment.
Effects of sevelamer and CaCO3 on secondary
hyperparathyroidism
As noted in Figure 1A, the average serum PTH in
untreated uremic rats fed a high phosphate diet was
2085  616 pg/mL with a 95% confidence interval (95%
CI) ranging from 503 to 3667 pg/mL. The elevation in
serum PTH induced by high dietary phosphorus in uremic
controls was markedly attenuated by treatment either with
sevelamer (528  158 pg/mL, P  0.01; 95% CI 122 to
934) or CaCO3 (708 285 pg/mL, P 0.01; 95% CI 0 to
1439). Mean serum PTH levels did not differ significantly
according to treatment with either sevelamer or CaCO3
(P  0.30). Mean serum PTH levels in nonuremic rats
fed a high phosphorus diet were 27.1  7.0 pg/mL; 95%
CI 9.2 to 44.8 (data not shown in Fig. 1A). Figure 1B
shows that untreated uremic rats developed a marked
increase in parathyroid gland weight (6.33  1.52 g/g
body weight) compared to uremic rats treated with phos-
phate binders. Treatment with both sevelamer (2.77 
0.27 g/g body weight, P  0.01) and CaCO3 (2.99 
0.39 g/g body weight, P  0.01) was associated with
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Fig. 1. Effects of sevelamer and calcium carbonate (CaCO3) on serum
parathyroid hormone (PTH) and parathyroid gland growth. Serum PTH
(A ) and parathyroid gland weight (B ) in uremic (5/6 nephrectomized)
rats undergoing one of the following experimental protocols for 6
months: () uremic control  high phosphorus diet (U-HP); ()
uremic  high phosphorus diet  3% sevelamer (U-HP  S); ( )
uremic  high phosphorus diet  3% CaCO3 (U-HP  C). Results
represent the mean  SEM from six rats per group. P values were
obtained by analysis of variance (ANOVA) and Bonferroni tests.
reduced enlargement of parathyroid glands compared to
uremic controls.
Effects of sevelamer and CaCO3 on calcium
deposition in kidney, myocardium, and aorta
Table 3 shows calcium content in kidney, myocardium,
and aorta in all experimental groups. All three groups
of uremic rats had markedly increased calcium deposi-
tion in the kidney compared to normal, nonuremic rats
fed the same high phosphate diet. However, a dramatic
reduction of renal calcium content was observed in the
sevelamer group compared to both uremic controls and
the CaCO3 group. Interestingly, myocardial calcium con-
tent was even higher in CaCO3 group than in uremic
controls. In contrast, sevelamer-treated rats developed
less myocardial calcium deposition compared to CaCO3-
treated rats. Untreated uremic rats had increased calcium
content in the aorta compared to normal rats. Sevelamer
treatment greatly reduced aortic calcium deposition
compared to both uremic controls and CaCO3-treated
rats.
Histologic effects of sevelamer and CaCO3
on kidney calcifications
Hematoxylin-eosin and von Kossa staining of repre-
sentative kidney sections from each experimental group
are shown in Figure 2. Kidney calcification was greater
in untreated uremic (Fig. 2 B and F) and CaCO3-treated
rats (Fig. 2 D and H) compared to normal animals (Fig.
2 A and E) fed the same high phosphate diet. Kidney
calcification was markedly lower in uremic rats treated
with sevelamer (Fig. 2 C and G). In addition, semiquanti-
tative analysis of kidney calcification (Fig. 3A) showed an
association between chemical measurement of calcium
content and the number of foci of calcification, being
lower in the sevelamer group than in uremic controls
and the CaCO3 group.
Histologic effects of sevelamer and CaCO3 on
myocardium and aortic calcifications
Figures 4 and 5 show representative myocardial and
aortic sections, respectively, from each experimental
group. Both hematoxylin-eosin and von Kossa staining
demonstrate the efficacy of sevelamer in attenuating cal-
cification of the myocardium and aorta. Myocardial (Fig.
4) and aortic (Fig. 5) sections from untreated (Fig. 4 B
and F and Fig. 5 B and F) and CaCO3-treated (Fig. 4 D
and H and Fig. 5 D and H) uremic rats showed more
calcification than normal animals (Fig. 4 A and E and
Fig. 5 A and E) and sevelamer-treated rats (Fig. 4 C and
G and Fig. 5 C and G). Calcifications in the myocardium
were specifically localized within capillaries, as demon-
strated in heart sections stained with an antibody to the
endothelial marker factor VIII (Fig. 6). No calcifications
were observed within the cardiac interstitium. Calcifica-
tions in the aorta were localized within the intimal and
medial layers. Figure 3 B and C also depict a higher
number of foci of calcification in the myocardium and
aorta of uremic controls and CaCO3-treated rats, which
parallels the higher calcium content in these tissues mea-
sured biochemically. Again, sevelamer-treated rats had
markedly reduced foci of calcification in myocardium
and aorta compared to the other two uremic groups.
DISCUSSION
These studies provide a long-term, experimental model
of the influence of uremia and the phosphate binders,
sevelamer and CaCO3, on vascular and kidney calcifica-
tion in rats with CRF. Aortic calcification was evident
after 6 months of uremia, unlike our previous 3-month
study [24]. Furthermore, despite a similar efficacy in con-
trolling serum phosphorus, Ca P product, and second-
ary hyperparathyroidism, those uremic rats treated with
sevelamer developed less vascular calcification in the
myocardium and aorta and less nephrocalcinosis com-
pared to uremic rats treated with CaCO3. Interestingly,
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Table 3. Calcium content in kidney, myocardium, and aorta
N-HP U-HP U-HP  S U-HP  C
Kidney calcium lg/g wet tissue 1129 1650286 582111a,b 1196180
Myocardial calcium lg/g wet tissue 535 9810 724b 17948
Aortic calcium lg/g wet tissue 39063 2150447 63696b,c 1308343
Renal calcium deposition in normal and uremic (5/6 nephrectomized) rats undergoing one of the following experimental protocols for 6 months: normal  high
phosphorus diet (N-HP), uremic control  HP diet (U-HP), uremic  HP diet  3% sevelamer (U-HP  S), uremic  HP diet  3% calcium carbonate (U-HP 
C). Values represent the mean  SEM from 12 different tissue samples of kidney, myocardium, and aorta.
aP  0.01 vs. U-HP, bP  0.05 vs. U-HP  C, cP  0.05 vs. U-HP from analysis of variance (ANOVA) and Bonferroni analysis
Fig. 2. Effects of sevelamer and calcium carbonate (CaCO3) on kidney calcification. Representative photomicrographs of hematoxylin-eosin (A
to D ) and von Kossa (E to H ) staining in remnant kidney tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental
protocols for 6 months: normal  high phosphorus diet (N-HP) (A and E), uremic control  high phosphorus diet (U-HP) (B and F), uremic 
high phosphorus diet 3% sevelamer (U-HP S) (C and G), uremic  high phosphorus diet  3% CaCO3 (U-HP C) (D and H). Magnification
400.
in those rats surviving to 6 months, treatment with seve-
lamer also attenuated the deterioration in renal function
seen in uremic controls and CaCO3-treated rats. Treat-
ment with either phosphate binder had no influence on
mortality compared to uremic controls.
In recent years, vascular calcification in patients with
CRF and end-stage renal disease (ESRD) has been in-
creasingly recognized as an important contributor to
overall cardiovascular morbidity and mortality. The ex-
act factors and mechanisms regulating vascular calcifica-
tion remain incompletely defined, yet there is increasing
evidence that this is an active, cell-mediated process [10–
11, 13–14, 25].
Many factors, such as high phosphorus, calcium, and
vitamin D therapy, may contribute to the development
of vascular calcification [25]. Various in vitro studies
have demonstrated that phosphorus and unidentified fac-
tors in uremic serum play a potential role in the patho-
genesis of vascular calcification [13–14]. Such studies
have demonstrated an increased expression of osteoblast-
specific proteins and calcification by vascular smooth
muscle cells in response to high levels of serum phospho-
rus and uremic serum. Hyperphosphatemia itself has
been identified as an independent risk factor for in-
creased cardiovascular mortality in patients with ESRD
[25]. Consequently, the control of hyperphosphatemia
with phosphate binders in patients with CRF and ESRD
has been appropriately emphasized.
Phosphate binders currently used to manage hyper-
phosphatemia in ESRD patients include sevelamer and
the calcium-containing binders, CaCO3, and calcium ace-
tate. Sevelamer is an aluminum- and calcium-free phos-
phate binder, which does not promote hypercalcemia
and has favorable effects on the lipid profile, with an
associated reduction in low-density lipoprotein (LDL)
and increase in high-density lipoprotein (HDL) choles-
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Fig. 3. Semiquantitative analysis of foci of calcifications in kidney, myo-
cardium, and aorta. Mean of foci of calcification in kidney (A ), myocar-
dium (B ), and aorta (C ) in uremic (5/6 nephrectomized) rats undergoing
one of the following experimental protocols for 6 months: () uremic
control high phosphorus diet (U-HP), () uremic high phosphorus
diet  3% sevelamer (U-HP  S), ( ) uremic  high phosphorus
diet  3% calcium carbonate (CaCO3) (U-HP  C). Normal rats do
not have any calcification. Results represent the Mean  SEM for
six rats per group. P values were obtained by analysis of variance
(ANOVA) and Bonferroni tests.
terol [21]. A potential concern with the use of calcium-
containing phosphate binders has been suggested over
the past few years. A study of young hemodialysis pa-
tients by Goodman et al [1] noted a correlation between
coronary artery calcification detected by electron beam
computed tomography and duration of dialysis, serum
phosphorus levels, serum Ca  P product, and daily
intake of calcium. Another study in 200 hemodialysis
patients by Chertow, Burke, and Raggi [15] showed that
sevelamer attenuated the progression of coronary and
aortic calcification better than calcium-based phosphate
binders after 1 year. Subjects treated with sevelamer had
lower serum calcium, total cholesterol, and LDL levels
compared to subjects treated with calcium-based phos-
phate binders. Thus, sevelamer’s effects on vascular cal-
cification may have been secondary to its lower calcium
load versus lipid-lowering properties. Furthermore, the
influence of type of the phosphate binder on cardiovascu-
lar morbidity and mortality has yet to be prospectively
studied in humans.
Our study in long-term experimental uremia shows
that treatment with sevelamer, when compared to CaCO3,
is associated with less vascular calcification within the
myocardium, aorta, and kidney. One potential explana-
tion for the increased vascular calcification in CaCO3-
treated rats could be the greater severity of renal dys-
function in this group compared to sevelamer-treated
rats. A recent in vitro study by Chen et al [14] demon-
strated that there are unidentified factors in uremic se-
rum that potentiate vascular calcification. In support of
this concept, uremic control rats in our study also had
worse renal function and excessive aortic calcification
compared to sevelamer-treated rats.
Hypothetically, a difference in lipid metabolism is yet
another potential contributing factor for the increased
vascular calicification noted in CaCO3-treated rats com-
pared to sevelamer-treated rats. In vitro studies have
shown that acetylated LDL stimulates [26] while HDL
inhibits [27] vascular smooth muscle cell calcification. In
our study, total cholesterol levels of CaCO3-treated rats
trended lower than sevelamer-treated rats, a finding
which could be explained by reduced dietary intake in
the setting of worse renal function. LDL and HDL levels
were not evaluated in our study. In human studies, seve-
lamer has been shown to consistently reduce LDL and
frequently increase HDL levels. Such an improved lipid
profile could potentially play a role in the lower degree
of vascular calcification seen in sevelamer-treated rats.
However, as already noted, the CaCO3-treated rats had
lower total cholesterol levels and LDL levels typically
parallel such levels.
In addition to a lower degree of vascular calcification,
treatment with sevelamer for 6 months was associated
with less kidney calcification compared to CaCO3. These
results are similar to those published by our group involv-
ing a 3-month experimental model of uremia. Interest-
ingly, as noted above, renal function, as measured by
serum creatinine, creatinine clearance, and proteinuria,
was preserved in those rats treated with sevelamer and
surviving to 6 months. The reason for this is unclear and
remains speculative. Nephrocalcinosis may have been a
contributing factor, as suggested by our previous studies
[24]. Uremic rats in each treatment group were fed a
diet with similar phosphorus and protein content, thus
minimizing the effect of other potential confounding fac-
tors known to influence the progression of renal failure.
It is important to note that, despite the preserved renal
function and lower vascular calcification in sevelamer-
treated rats, there were high mortality rates in all uremic
groups, which did not differ significantly.
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Fig. 4. Effects of sevelamer and calcium carbonate (CaCO3) on myocardial calcification. Representative photomicrographs of hematoxylin-eosin
(A to D ) and von Kossa (E to H ) staining in myocardial tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental
protocols for 6 months: normal  high phosphorus diet (N-HP) (A and E), uremic control  high phosphorus diet (U-HP) (B and F), uremic 
high phosphorus diet 3% sevelamer (U-HP S) (C and G), uremic  high phosphorus diet 3% CaCO3 (U-HP  C) (D and H). Magnification
400.
Fig. 5. Effects of sevelamer and calcium carbonate (CaCO3) on aortic calcification. Representative photomicrographs of hematoxylin-eosin (A to
D ) and von Kossa (E to H ) staining in aortic tissue of normal and 5/6 nephrectomized rats undergoing one of the following experimental protocols
for 6 months: normal  high phosphorus diet (N-HP) (A and E), uremic control  high phosphorus diet (U-HP) (B and F), uremic  high
phosphorus diet  3% sevelamer (U-HP  S) (C and G), uremic  high phosphorus diet  3% CaCO3 (U-HP  C) (D and H). Magnification
400.
Cozzolino et al: Advantage of Sevelamer as a phosphate-binder 1661
Fig. 6. Intravascular localization of myocardial calcification. Represen-
tative photomicrograph demonstrating calcifications within myocardial
capillaries. Calcifications and factor VIII (a specific endothelial cell
marker) stain brown (magnification 800).
CONCLUSION
These studies of long-term experimental uremia sug-
gest that, despite similar control of hyperphosphatemia
and other markers of secondary hyperparathyroidism,
sevelamer may be more effective than CaCO3 in attenu-
ating cardiovascular and kidney calcification. Potential
mechanisms mediating these differences are only in the
early stages of elucidation.
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